Dimebutic acid(Dimebutic acid) - 药物靶点：β-globin_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

β-globin

作用方式

刺激剂

作用机制

β-globin刺激剂(血红蛋白β链刺激剂)

治疗领域

遗传病与畸形血液及淋巴系统疾病其他疾病

在研适应症-

非在研适应症

镰状细胞血症β地中海贫血地中海贫血

原研机构

Boston University

在研机构-

非在研机构

HemaQuest Pharmaceuticals, Inc.

Boston University

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C6H12NaO2

InChIKeyQHLWRCHRKPPHNM-UHFFFAOYSA-N

CAS号3934-02-9

查看全部结构式(2)

关联

6

项与 Dimebutic acid 相关的临床试验

NCT01601340

/ Terminated临床2期

A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease

The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.

开始日期2012-07-01

申办/合作机构

HemaQuest Pharmaceuticals, Inc.

NCT01642758

/ Completed临床2期IIT

An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia

Beta thalassemia intermedia syndromes are genetic anemias caused by mutations which reduce production of beta globin, a major component of adult hemoglobin A, the protein which delivers oxygen throughout the body. Patients suffer from poor growth, fatigue, heart failure, endocrine deficiencies, and eventually, many require chronic blood transfusions. There is no approved therapeutic for the deficiency of beta globin chains in beta thalassemia.
This trial will study an oral therapeutic which stimulates production of fetal globin, an alternate type which is produced by all humans, but is normally switched off in infancy. This type of globin can compensate for the missing protein in beta thalassemia.

开始日期2012-05-01

申办/合作机构

Boston University

[+1]

NCT01322269

/ Completed临床2期

A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease

The purpose of this study is to evaluate the safety and tolerability of three dose levels of HQK-1001 administered once daily for 26 weeks in subjects with sickle cell disease.

开始日期2011-04-01

申办/合作机构

HemaQuest Pharmaceuticals, Inc.

100 项与 Dimebutic acid 相关的临床结果

登录后查看更多信息

100 项与 Dimebutic acid 相关的转化医学

登录后查看更多信息

100 项与 Dimebutic acid 相关的专利（医药）

登录后查看更多信息

577

项与 Dimebutic acid 相关的文献（医药）

2025-03-28·Organic Letters

Palladium-Catalyzed Directed Alkenylation of Alkyl Amides with Unactivated Alkenes: Access to γ-Alkenyl γ-Lactams

Article

作者: Barman, Madhab ; Mandal, Santu ; Punniyamurthy, Tharmalingam ; Nanjegowda, Maniya V.

Pd(II)-catalyzed cascade C(sp³)-H alkenylation and cyclization of alkyl amides with readily accessible unactivated alkenes have been accomplished. Alkenylation and subsequent intramolecular cyclization empowered the formation of functionalized γ-lactams, which present as an active core of several bioactive and natural products. The use of catalytic Cu(OAc)₂ along with molecular oxygen as the oxidant, a 2-chloropyridine ligand, site selectivity, the substrate scope, and gram-scale synthesis are important practical features.

2025-03-14·The Journal of Organic Chemistry

Decarboxylative Alkylation of Morita–Baylis–Hillman Acetates with Aliphatic Acids via Photochemical Iron-Mediated Ligand-to-Metal Charge Transfer

Article

作者: Jing, Lin-Hai ; Mei, Yu-Tong ; Guo, Zi-Yi ; Zhang, Hui ; Zheng, Yu-Xuan ; Shi, Ming-Song ; Hou, Qiu-Yao ; Yang, Dan ; Cheng, De-Jun

Carboxylic acids are bench-stable and readily available chemical feedstocks that function as optimal and fundamental synthetic platforms for the construction of C(sp³)-C(sp³) bonds via decarboxylation processes. We present a novel and practical protocol for the decarboxylative alkylation of Morita-Baylis-Hillman acetates with various carboxylic acids via a photoinduced iron-mediated ligand-to-metal charge transfer (LMCT) process under redox-neutral conditions. This method exhibits remarkable tolerance to a wide array of carboxylic acids, including primary, secondary, and tertiary carboxylic acids, obviating the requirement for preactivated radical precursors. The preliminary mechanistic analyses indicate that a radical pathway is involved in this catalytic transformation.

2025-03-07·Organic Letters

Synthesis of γ-Lactams via Palladium-Catalyzed C(sp³)–H Bond Activation of Alkyl Sulfonamides with Substituted Alkenes

Article

作者: Dutta, Ananya ; Jeganmohan, Masilamani

A methodology for the γ-butyrolactam scaffolds via ligand-enabled C(sp³)-H bond functionalization of sulfonamides with olefins has been demonstrated. The protocol has been found to be compatible with several activated and unactivated olefins, and the desired lactams were formed in excellent yields. A plausible mechanism has been described to account for the desired lactamization reaction as well as supported by mechanistic investigation including a ¹H NMR study and isolation of a palladacycle intermediate.

1

项与 Dimebutic acid 相关的新闻（医药）

2008-12-09

·BioSpace

HemaQuest Announces Clinical Progress on New Sickle Cell Anemia Drug

SAN FRANCISCO, CA--(Marketwire - December 09, 2008) - HemaQuest Pharmaceuticals announced today the successful completion of Phase 1 clinical trials of HQK-1001, an orally-administered therapeutic which the company is developing to treat hemoglobin disorders, including sickle cell anemia and beta thalassemia. The company presented the results at the annual meeting of the American Society of Hematology in San Francisco.

100 项与 Dimebutic acid 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
β地中海贫血	临床2期	黎巴嫩	HemaQuest Pharmaceuticals, Inc.	2012-05-01
镰状细胞血症	临床2期	黎巴嫩	HemaQuest Pharmaceuticals, Inc.	2011-04-01
镰状细胞血症	临床2期	美国	HemaQuest Pharmaceuticals, Inc.	2011-04-01
镰状细胞血症	临床2期	加拿大	HemaQuest Pharmaceuticals, Inc.	2011-04-01
镰状细胞血症	临床2期	牙买加	HemaQuest Pharmaceuticals, Inc.	2011-04-01
镰状细胞血症	临床2期	埃及	HemaQuest Pharmaceuticals, Inc.	2011-04-01
地中海贫血	临床2期	-	Boston University	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01601340 (Pubmed \| Am J Hematol)	临床2期	镰状细胞血症	76	HQK-1001	獵積顧築蓋鹽壓齋窪網(廠廠鹽醖鬱淵製糧壓觸) = The most common adverse events in the HQK-1001 group, usually graded as mild or moderate, consisted of abdominal pain 鏇夢築繭築鹹廠鹹鬱鬱 (夢襯鬱遞遞廠憲襯衊簾 ) 更多	不佳	2014-07-01
				Placebo